What is nontuberculous mycobacteria infection?

Nontuberculous mycobacterial (NTM) lung disease is a serious infection caused by bacteria that are common in the environment and can cause lung damage. They are aerosolized, which means that the bacteria can exist in water and soil particles that are in the air.

Is NTM a rare disease?

Today, Insmed’s primary area of focus is on patients with nontuberculous mycobacterial (NTM) lung disease, a rare and serious disorder that can significantly increase morbidity and mortality. Mycobacterium avium complex (MAC) is the group of bacteria that most commonly causes NTM lung disease.

Is nontuberculous mycobacterial lung disease contagious?

NTM disease is not contagious. More than 86,000 people are likely living with NTM lung disease in the U.S. Rates appear to be increasing, especially among women and older age groups.

What are the symptoms of NTM?

What are the symptoms of NTM infections?

cough, and coughing up sputum or blood.
fever.
losing weight and loss of appetite.
feeling very tired.
increasing shortness of breath.
night sweats.

How long can you live with NTM lung disease?

The median survival time was 13.0 years (95 % CI 5.9–20.1) for pulmonary MAC but 4.6 years (95 % CI 3.4–5.9) for pulmonary other NTM.

Is NTM serious?

They’re harmless to most people. But sometimes when these bacteria get into your body, they can cause a serious lung disease. NTM infections are becoming more common, especially among people ages 65 and older.

What are the NTM lung disease treatment guidelines?

The guidelines, published in Clinical Infectious Diseases and accessible here, are the globally recognized standard for the prevention, diagnosis, and treatment of NTM lung disease with the goal of providing the latest evidence-based guidance to improve patient care and outcomes.

Why choose INSMED?

Insmed conducts research in-house to potentially bring forth new medicines and technologies that address rare and serious diseases. * In the U.S., as a condition of accelerated approval, Insmed is conducting an additional clinical study to support full approval.